{"id":"gardasil-9-suspension-for-injection","safety":{"commonSideEffects":[{"rate":"48-61%","effect":"Injection site pain"},{"rate":"25-29%","effect":"Injection site swelling"},{"rate":"24-34%","effect":"Injection site erythema"},{"rate":"11-16%","effect":"Headache"},{"rate":"1-3%","effect":"Fever"},{"rate":"4-6%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains virus-like particles (VLPs) derived from the L1 major capsid protein of nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against these HPV types, preventing viral infection of epithelial cells and reducing the risk of HPV-related malignancies and benign lesions.","oneSentence":"Gardasil 9 is a recombinant human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against nine HPV types to prevent infection and associated cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:57.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58"},{"name":"Prevention of anal cancer caused by HPV types 16 and 18"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of oropharyngeal and other HPV-related cancers"}]},"trialDetails":[{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04982614","phase":"PHASE4","title":"HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini","status":"COMPLETED","sponsor":"Columbia University","startDate":"2022-04-01","conditions":"HPV Infection, Hiv, HPV Vaccine","enrollment":1403},{"nctId":"NCT06799494","phase":"PHASE4","title":"HPV Vaccine Reduced Dose","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-08-06","conditions":"HPV","enrollment":100},{"nctId":"NCT05625633","phase":"PHASE2, PHASE3","title":"Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts","status":"RECRUITING","sponsor":"Western Institute for Veterans Research","startDate":"2024-03-25","conditions":"Warts","enrollment":120},{"nctId":"NCT06207175","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine","status":"UNKNOWN","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2023-11-21","conditions":"Human Papillomavirus Infection","enrollment":1260},{"nctId":"NCT06052696","phase":"PHASE4","title":"Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-12-01","conditions":"Vulvar HSIL, HPV","enrollment":500},{"nctId":"NCT05662020","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2022-03-23","conditions":"Human Papillomavirus Infection","enrollment":2750}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gardasil 9 Suspension for Injection","genericName":"Gardasil 9 Suspension for Injection","companyName":"Erasmus Medical Center","companyId":"erasmus-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gardasil 9 is a recombinant human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against nine HPV types to prevent infection and associated cancers. Used for Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58, Prevention of anal cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}